Glenmark Pharmaceuticals FY26 Annual Earnings Summary

The Monroe facility has five FDA observations; management is awaiting FDA response and hopes to restart commercial manufacturing this year, but timeline is uncertain.

FLOVENT 44 approval is pending; any delay could impact Q4 US revenue growth.

Glenmark USA is involved in multidistrict antitrust litigation; settled with direct purchaser class for $37.75M, but other classes remain, with no visibility on timeline.

India reported growth of 3.7% lags secondary sales growth of 15.1% due to tail-end brand discontinuations; convergence expected only from Q3.

The unexpected GST regime change caused a one-time reduction in distributor inventories, impacting primary sales. While management expects normalization, future regulatory changes could again disrupt the three-tier model.

Analysts questioned the frequency of write-offs (Monroe, litigation, India). Management assured no further corrections, but past unpredictability raises concerns about controls.

Analyst questioned the quantum of currency benefit; management could not quantify, indicating potential overstatement of organic growth.

Excluding out-licensing income, gross margin was lower at 65% due to product mix; recovery depends on new approvals.

Net debt increased to INR 1,500 crore due to inventory buildup for launches and one-time payments; management expects stabilization but no specific timeline.

Management confirmed litigation cash outflows of slightly less than INR 800 crore over the next few years, which could pressure cash flows if not managed.

Despite progress, working capital days remain a focus; any slippage could impact cash flow targets.